| |
| |
| Exchange: |
N/A |
| Security
Type: |
N/A |
| Shares
Out: |
232,140,000 |
| Market
Cap: |
1.57(B) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$3.23 - $9.74 |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Ardelyx is a biopharmaceutical company focused on discovering, developing and commercializing medicines. This includes adult patients with irritable bowel syndrome with constipation (IBS-C), adult patients with chronic kidney disease (CKD) on dialysis suffering from elevated serum phosphorus, or hyperphosphatemia; and adult patients with CKD and/or heart failure with elevated serum potassium, or hyperkalemia. Co.'s product pipeline includes among other, IBSRELA, a sodium hydrogen exchanger 3 inhibitor for the treatment of IBS-C in adults; and XPHOZAH, which is a medicine being developed for the control of serum phosphorus in adult patients with CKD on dialysis.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
585,000 |
| Total Buy Value |
$0 |
$0 |
$0 |
$1,011,778 |
| Total People Bought |
0 |
0 |
0 |
7 |
| Total Buy Transactions |
0 |
0 |
0 |
7 |
| Total Shares Sold |
780,776 |
1,206,168 |
1,357,304 |
2,009,275 |
| Total Sell Value |
$6,635,429 |
$9,420,070 |
$9,994,774 |
$10,729,161 |
| Total People Sold |
8 |
8 |
8 |
8 |
| Total Sell Transactions |
19 |
37 |
60 |
105 |
| End Date |
2024-02-25 |
2023-11-24 |
2023-05-26 |
2022-05-26 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Jenkins Annalisa |
Director |
– • – |
2019-06-13 |
4 |
A |
$0.00 |
$0 |
D/D |
20,072 |
33,471 |
|
- |
|
| Rodgers Richard J |
Director |
– • – |
2019-06-13 |
4 |
A |
$0.00 |
$0 |
D/D |
24,635 |
68,377 |
|
- |
|
| Mott David M |
Director |
– • • |
2019-06-13 |
4 |
A |
$0.00 |
$0 |
D/D |
32,846 |
87,566 |
|
- |
|
| Lundberg Jan M |
Director |
– • – |
2019-06-13 |
4 |
A |
$0.00 |
$0 |
D/D |
17,335 |
29,121 |
|
- |
|
| Bertrand William C Jr |
Director |
– • – |
2019-06-13 |
4 |
A |
$0.00 |
$0 |
D/D |
18,248 |
52,135 |
|
- |
|
| Raab Michael |
President & CEO |
• • – |
2019-06-04 |
4 |
S |
$2.54 |
$25,551 |
D/D |
(10,054) |
254,355 |
|
- |
|
| Grammer Elizabeth A |
SVP, General Counsel |
• – – |
2019-06-04 |
4 |
S |
$2.54 |
$6,404 |
D/D |
(2,520) |
126,764 |
|
- |
|
| Rosenbaum David P. |
Chief Development Officer |
• – – |
2019-06-04 |
4 |
S |
$2.54 |
$7,258 |
D/D |
(2,856) |
160,171 |
|
- |
|
| Kaufmann Mark |
Chief Financial Officer |
• – – |
2019-06-04 |
4 |
S |
$2.55 |
$8,551 |
D/D |
(3,357) |
139,088 |
|
- |
|
| Grammer Elizabeth A |
SVP, General Counsel |
• – – |
2019-05-31 |
4 |
GA |
$0.00 |
$0 |
I/I |
1,000 |
2,000 |
|
- |
|
| Grammer Elizabeth A |
SVP, General Counsel |
• – – |
2019-05-31 |
4 |
GD |
$0.00 |
$0 |
D/D |
3,000 |
129,284 |
|
- |
|
| Kaufmann Mark |
Chief Financial Officer |
• – – |
2019-01-02 |
4 |
S |
$1.70 |
$11,154 |
D/D |
(6,556) |
139,933 |
|
- |
|
| Raab Michael |
President & CEO |
• • – |
2019-01-02 |
4 |
S |
$1.70 |
$33,418 |
D/D |
(19,644) |
261,409 |
|
- |
|
| Rosenbaum David P. |
Chief Development Officer |
• – – |
2019-01-02 |
4 |
S |
$1.70 |
$1,363 |
I/I |
(801) |
18,029 |
|
- |
|
| Rosenbaum David P. |
Chief Development Officer |
• – – |
2019-01-02 |
4 |
S |
$1.70 |
$9,503 |
D/D |
(5,585) |
160,027 |
|
- |
|
| Grammer Elizabeth A |
EVP, General Counsel |
• – – |
2019-01-02 |
4 |
S |
$1.70 |
$8,370 |
D/D |
(4,920) |
129,284 |
|
- |
|
| Grammer Elizabeth A |
EVP, General Counsel |
• – – |
2018-11-13 |
4 |
S |
$2.84 |
$18,571 |
D/D |
(6,539) |
134,204 |
|
- |
|
| Rosenbaum David P. |
Chief Development Officer |
• – – |
2018-11-13 |
4 |
S |
$2.84 |
$15,819 |
D/D |
(5,570) |
165,612 |
|
- |
|
| Kaufmann Mark |
Chief Financial Officer |
• – – |
2018-11-13 |
4 |
S |
$2.84 |
$18,571 |
D/D |
(6,539) |
146,489 |
|
- |
|
| Raab Michael |
President & CEO |
• • – |
2018-11-13 |
4 |
S |
$2.84 |
$18,571 |
D/D |
(6,539) |
292,499 |
|
- |
|
| Sandell Scott D |
10% Owner |
– – • |
2018-11-12 |
4 |
S |
$2.98 |
$1,767 |
I/I |
(592) |
0 |
|
- |
|
| Grammer Elizabeth A |
EVP, General Counsel |
• – – |
2018-09-21 |
4 |
GD |
$0.00 |
$0 |
D/D |
3,000 |
140,743 |
|
- |
|
| Grammer Elizabeth A |
EVP, General Counsel |
• – – |
2018-09-21 |
4 |
GA |
$0.00 |
$0 |
I/I |
1,000 |
1,000 |
|
- |
|
| Raab Michael |
President & CEO |
• • – |
2018-07-26 |
4 |
A |
$0.00 |
$0 |
D/D |
200,000 |
299,038 |
|
- |
|
| Rosenbaum David P. |
Chief Development Officer |
• – – |
2018-07-26 |
4 |
A |
$0.00 |
$0 |
I/I |
10,000 |
17,045 |
|
- |
|
540 Records found
|
|
Page 13 of 22 |
|
|
0.69 (9.27%) 
